New Hope for Huntington Disease Treatment Addressing Root Cause for First Time

New Hope for Huntington Disease Treatment Addressing Root Cause for First Time

New Hope for Huntington Disease Treatment Addressing Root Cause for First Time Inspiring Affected Canadians to Step Forward for First Time Inspiring Affected Canadians to Step Forward


…Toronto event on March 23 will shed light on changing landscape of the disease including progress of clinical trials, genetic testing and Canadian research…


(KITCHENER, ON) March 12, 2019 – The Huntington Society of Canada is urging Canadians with a family history of Huntington disease (HD) to come forward to learn about the changing landscape of HD. On March 23, the Society is hosting an interactive expert panel discussion in Toronto to present the latest research advancements, genetic testing options and local clinical trials to individuals and families affected by the disease.


“This is a hopeful and exciting time for the Huntington disease community with more Canadians participating in HD initiatives than ever before,” said Robin Markowitz, CEO, Huntington Society of Canada. “For the first time, drugs are in clinical trials that address the root cause of Huntington disease. There are currently seven different clinical trials happening at centres across Canada. Finding treatments for HD will take the collective efforts of researchers, scientists, clinicians, the Huntington Society of Canada and HD families, so it’s imperative we all work together. It is our best chance for success.”


Huntington disease is a debilitating brain disorder that is fatal and incurable. HD causes cells in specific parts of the brain to die. As the disease progresses, a person with Huntington disease becomes less able to manage movements, recall events, make decisions and control emotions. Many describe the symptoms of HD like having ALS, Parkinson’s and Alzheimer’s simultaneously. HD is genetic, parents have a 50 per cent chance of passing the gene onto their children.


“Huntington disease has been called ‘the most curable incurable disease’ because we know what we have to do to prevent and treat it. But until now there has been little progress made in the way of medications to help treat HD so there has been a sense of futility in the HD community,” said Dr. Mark Guttman, a neurologist, lead clinical trials researcher, and one of the event panelists’, “Because of this, some choose not to be involved with the HD community, receive genetic counselling or testing or participate in clinical trials. That’s why it’s more important than ever to reach patients and their families who haven’t previously been active members of the HD community. Because today, there is hope.”


The Changing Landscape of Huntington Disease event presented by The Huntington Society of Canada at North York General Hospital on Saturday March 23 will feature:


  • Clinical trial presentation and Q&A with clinical trials lead by Dr. Mark Guttman MD FRCPC from the Centre of Movement Disorders
  • Genetics Primer presentation by Clare Gibbons, Manager of Clinical Genetics, will discuss the basics of Huntington disease genetics and what to expect in genetic testing process


To register or for more information about the event visit



The Huntington Society of Canada (HSC) is a respected leader in the worldwide effort to end Huntington disease. HSC is the only Canadian health charity dedicated to providing help and hope for families dealing with Huntington disease across Canada. HSC plays a key role in bridging the relationship between researchers and individuals by educating Canadians on the importance of the clinical trial process, how to get involved and why participation is so crucial. For more information visit


# # #


Media Contacts:


Jeffrey Hoffman

Director, Development and Marketing

Huntington Society of Canada

1-800-998-7398 Ext. 125


Karina Moskvitin / Katherine Clark

Cowan & Company Communications

416-462-8773 /